Department of Operating Room, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
Department of Anesthesiology, Shanghai East Hospital, School of Medicine, Tongji University, 200120 Shanghai, China.
Front Biosci (Landmark Ed). 2024 Feb 23;29(2):89. doi: 10.31083/j.fbl2902089.
Aberrant splicing has been closely associated with human cancer, though the precise underlying mechanisms linking the two remain not fully understood. Investigating the role of splicing factors in cancer progression may aid in the development of targeted therapies for dysregulated splicing, thereby opening up new avenues for cancer treatment. RNA-binding motif 4 (RBM4) has been identified as a critical participant in the condensin II complex, which is involved in chromosome condensation and stabilization during mitosis. Its significance in tumors is currently gaining attention. The genetic characteristics of RBM4 suggest its potential to elucidate the malignant progression of tumors in a broader context, encompassing various types of cancer, known as pan-cancer.
This study aims to comprehensively explore the potential function of RBM4 in pan-cancer by leveraging existing databases such as The Cancer Genome Atlas (TCGA) and Genotype-Tissue Expression (GTEx).
RBM4 is found to be overexpressed in almost all tumors and exhibits significant prognostic and diagnostic efficacy. The correlation between RBM4 and immune signatures, including immune cell infiltration and immune checkpoint genes, indicates that RBM4 could serve as a guiding factor for immunotherapy.
As a member of the pan-oncogene, RBM4 has the potential to become a biomarker and therapeutic target for various malignant tumors, offering novel possibilities for precision medicine.
异常剪接与人类癌症密切相关，尽管将两者联系起来的精确潜在机制仍不完全清楚。研究剪接因子在癌症进展中的作用可能有助于开发针对失调剪接的靶向治疗，从而为癌症治疗开辟新途径。RNA 结合基序 4（RBM4）已被确定为参与有丝分裂过程中染色体浓缩和稳定的凝聚素 II 复合物的关键参与者。它在肿瘤中的意义目前引起了关注。RBM4 的遗传特征表明，它有可能在更广泛的范围内阐明肿瘤的恶性进展，包括各种类型的癌症，称为泛癌。
本研究旨在通过利用癌症基因组图谱 (TCGA) 和基因型组织表达 (GTEx) 等现有数据库，全面探讨 RBM4 在泛癌中的潜在功能。
RBM4 在几乎所有肿瘤中均过度表达，并表现出显著的预后和诊断效果。RBM4 与免疫特征（包括免疫细胞浸润和免疫检查点基因）之间的相关性表明，RBM4 可以作为免疫治疗的指导因素。
作为泛癌基因的一员，RBM4 有可能成为各种恶性肿瘤的生物标志物和治疗靶点，为精准医学提供新的可能性。
